Key facts
- Manuals
- 1
- Languages
- ZH
- Last added
- 2023-11-17
Featured Borui Biopharmaceuticals (Suzhou) manuals

Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing
This 464-page document contains Borui Biopharmaceuticals (Suzhou) Co., Ltd.'s detailed responses to the first round of inquiry letters from the Shanghai Stock Exchange concerning its IPO application on the Sci-Tech Innovation Board (STAR Market). Prepared with sponsor Minsheng Securities, the response addresses 49 questions across seven sections: equity structure and management basics, core technology, business operations, corporate governance and independence, financial accounting and management analysis, risk disclosures, and other matters. The excerpt shows detailed disclosure of new shareholders added in the prior year, including corporate shareholders Giant Sun and Guofa Qianhe, and partnership shareholders such as Sequoia Zhisheng, Hongpeng Investment, and Longmen Investment, with their equity structures and general partner information. This manual is written in Chinese.
Covers: Equity structure and management basics · Core technology · Business operations · Corporate governance and independence · Financial accounting and management analysis · Risk disclosures
Latest Borui Biopharmaceuticals (Suzhou) manuals
Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing
Other 464 pages · 3.9 MB · ZHResponse document to Shanghai Stock Exchange inquiry letters regarding Borui Biopharmaceuticals' initial public offering and STAR Market listing…
Questions answered in Borui Biopharmaceuticals (Suzhou) manuals
Who are the new corporate shareholders added in the year before the IPO inquiry response?
The new corporate shareholders are Giant Sun Investments HK Limited and Guofa Qianhe Investment Co., Ltd.
From: Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing
What is the equity structure of Giant Sun Investments HK Limited?
Giant Sun is 100% owned by HL Partners II L.P.
From: Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing
